NOVN.CH

91.26

+1.16%↑

NOVN.CH

91.26

+1.16%↑

NOVN.CH

91.26

+1.16%↑

NOVN.CH

91.26

+1.16%↑

NOVN.CH

91.26

+1.16%↑

Search

Lonza Group AG

Fermé

SecteurSoins de santé

571.6 0.99

Résumé

Variation du prix de l'action

24h

Actuel

Min

566

Max

573.6

Chiffres clés

By Trading Economics

Revenu

-22M

307M

Ventes

460M

3.5B

P/E

Moyenne du Secteur

64.697

56.602

BPA

4.31

Rendement du dividende

0.69

Marge bénéficiaire

8.729

Employés

17,995

EBITDA

-60M

764M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+13.04% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.69%

2.45%

Prochains Résultats

23 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-561M

42B

Ouverture précédente

570.61

Clôture précédente

571.6

Sentiment de l'Actualité

By Acuity

14%

86%

14 / 382 Classement par Healthcare

Lonza Group AG Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 mai 2025, 05:18 UTC

Résultats

Lonza Doesn't Expect Tariff Hit, Backs Outlook for CDMO Business

18 févr. 2025, 12:22 UTC

Acquisitions, Fusions, Rachats

Lonza Picks BofA, Centerview Partners for Capsules Unit Sale, Bloomberg Law Says, Citing Sources

12 déc. 2024, 09:26 UTC

Acquisitions, Fusions, Rachats

Lonza Streamlines Business With Capsules Unit Exit -- 2nd Update

12 déc. 2024, 07:45 UTC

Acquisitions, Fusions, Rachats

Lonza Streamlines Business With Capsules Unit Exit -- Update

12 déc. 2024, 06:52 UTC

Acquisitions, Fusions, Rachats

Lonza Streamlines Organizational Structure

9 mai 2025, 14:45 UTC

Market Talk

Big Pharma's U.S. Expansion Will Take Years to Materialize, Lonza CFO Says -- Market Talk

9 mai 2025, 14:42 UTC

Market Talk

Big Pharma U.S. Investment Plans Might Not Bring Extra Spending, Lonza CFO Says -- Market Talk

8 avr. 2025, 07:34 UTC

Market Talk

Lonza Well Protected From Tariffs -- Market Talk

29 janv. 2025, 08:11 UTC

Market Talk
Résultats

Lonza's Outlook Looks Positive -- Market Talk

29 janv. 2025, 07:22 UTC

Market Talk
Résultats

Lonza Had a Mixed Year Across Divisions -- Market Talk

29 janv. 2025, 07:11 UTC

Market Talk
Résultats

Lonza's Results Don't Contain Any Surprises -- Market Talk

29 janv. 2025, 06:26 UTC

Actualités
Résultats

Lonza Posts Lower Sales, Earnings But Expects Capsules Business Rebound This Year

16 janv. 2025, 10:32 UTC

Market Talk
Acquisitions, Fusions, Rachats

Lonza's Midterm Outlook Is Positive -- Market Talk

16 déc. 2024, 22:03 UTC

Actualités

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

13 déc. 2024, 08:07 UTC

Market Talk
Acquisitions, Fusions, Rachats

Lonza Unlikely to Pursue Large Acquisitions -- Market Talk

12 déc. 2024, 08:51 UTC

Market Talk
Résultats
Acquisitions, Fusions, Rachats

Lonza's Exit of Capsules Business Is a Positive Move -- Market Talk

12 déc. 2024, 08:02 UTC

Market Talk
Acquisitions, Fusions, Rachats

Lonza's Divestiture of Capsules Division Shouldn't Surprise -- Market Talk

12 déc. 2024, 05:59 UTC

Acquisitions, Fusions, Rachats

Lonza Targets Dividend Pay-Out Ratio Between 35%-45%

12 déc. 2024, 05:59 UTC

Acquisitions, Fusions, Rachats

Lonza Confirms Div Policy; to Maintain or Increase Div Per Shr Year-on-Year

12 déc. 2024, 05:58 UTC

Acquisitions, Fusions, Rachats

Lonza Sees Low-To-Mid Single-Digit CER Sales Growth Beyond 2025

12 déc. 2024, 05:58 UTC

Acquisitions, Fusions, Rachats

Lonza Sees CHI Core Ebitda Margin in the Mid-Twenties for 2025

12 déc. 2024, 05:58 UTC

Acquisitions, Fusions, Rachats

Lonza Sees Gradual Return to Previous Core Ebitda Margin Beyond 2025

12 déc. 2024, 05:57 UTC

Acquisitions, Fusions, Rachats

Lonza Sees Low-To-Mid Single-Digit CHI Sales Growth for 2025

12 déc. 2024, 05:55 UTC

Acquisitions, Fusions, Rachats

Lonza Sees Core 2025 Ebitda Growth Ahead of Sales Growth

12 déc. 2024, 05:54 UTC

Acquisitions, Fusions, Rachats

Lonza CHF 2025 Sales From Vacaville, Core Ebitda Margin Approaching 30%

12 déc. 2024, 05:54 UTC

Acquisitions, Fusions, Rachats

Lonza CDMO 2025 Outlook Approaching 20% Sales Growth in CER

12 déc. 2024, 05:53 UTC

Acquisitions, Fusions, Rachats

Lonza Sees 2024 Core Ebitda Margin of 27-29%

12 déc. 2024, 05:53 UTC

Acquisitions, Fusions, Rachats

Lonza Sees Flat 2024 CER Sales Growth

12 déc. 2024, 05:52 UTC

Acquisitions, Fusions, Rachats

Lonza Backs 2024 View

12 déc. 2024, 05:52 UTC

Acquisitions, Fusions, Rachats

Lonza: CDMO Business to Be Structured Into Three New Business Platforms

Comparaison

Variation de prix

Lonza Group AG prévision

Objectif de Prix

By TipRanks

13.04% hausse

Prévisions sur 12 Mois

Moyen 645 CHF  13.04%

Haut 670 CHF

Bas 630 CHF

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

3

Achat

1

Maintien

0

Vente

Sentiment

By Acuity

14 / 382Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.